论文部分内容阅读
目的 通过对肺癌患者血清p5 3抗体水平与肺癌临床指标关系的研究 ,探讨血清 p5 3抗体在肺癌中的临床意义。 方法 对 6 8例肺癌患者应用ELISA法检测血清 p5 3抗体滴度 ,经酶联免疫检测仪测吸光值E4 50 ,计算抗体指数 ,进行统计学分析。结果 6 8例中阳性 32例 ,阳性率为 47.1%。血清 p5 3抗体水平与肺癌的一般临床特征 ,如性别、分期、吸烟指数、既往治疗均无关 ,而与肺癌的病理类型和肿块大小有关。结论 p5 3抗体的产生可能是肺癌发生的早期指征 ,是肺癌的不良预后因子 ,有望应用于预测复发和评价疗效。
Objective To investigate the clinical significance of serum p5 3 antibody in lung cancer by studying the relationship between the level of serum p5 3 antibody in lung cancer patients and clinical indicators of lung cancer. Methods The serum antibody titers of p5 3 were detected by enzyme-linked immunosorbent assay (ELISA) in 68 patients with lung cancer, and the antibody index was calculated by the absorbance value of E4 50 by enzyme-linked immunosorbent assay. Statistical analysis was performed. Results of 68 cases positive in 32 cases, the positive rate was 47.1%. Serum p5 3 antibody levels and the general clinical features of lung cancer, such as gender, stage, smoking index, previous treatment have nothing to do with the pathological type of lung cancer and tumor size. Conclusion The production of p5 3 antibody may be an early indicator of lung cancer. It is a poor prognostic factor for lung cancer and is expected to be used to predict the recurrence and evaluate the curative effect.